Astellas Pharma Inc. (ALPMY) Stock Price & Analysis
Astellas Pharma Inc. (ALPMY) is trading at USD 15.91, up 0.76% today, as of October 23, 2026 at 16:15 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ALPMY last closed at USD 15.79; today's session has ranged USD 15.91–15.92 on volume of 800 shares. Market capitalization is $28.53B, with a 52-week range of USD 10.05–17.35 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALPMY.md
Key facts (ALPMY)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 17.4 (range 17.4–17.4).
- Total return with dividends: 1Y +48.5% vs S&P 500 +14.6%; 5Y -1.2% vs S&P 500 +77.3%.
- Next earnings: 2026-11-04, EPS estimate USD —, revenue estimate $594B.
Analysts (ALPMY)
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 17.4 (low 17.4, high 17.4).
Total return (dividends reinvested) (ALPMY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +48.5% | -1.2% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +48.6% | -0.2% |
| Volatility (annualized) | 29.8% | 25.6% |
| Max drawdown | -22.3% (Apr 2026→Jul 2026) | -47.0% (Nov 2021→Apr 2025) |
ALPMY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $594.09B | — |
| Next quarter (ends Dec 2026) | — | — | — | $616.88B | — |
| Current fiscal year (ends Mar 2027) | $1.23 | $1.31 | -6.4% | $2.37T | 1 |
| Next fiscal year (ends Mar 2028) | $1.14 | $1.17 | -3.0% | $2.21T | 1 |
Key Statistics (as of October 23, 2026 at 16:39 UTC)
| Price | USD 15.91 |
|---|---|
| Change | ▲ 0.76% (up) |
| Previous Close | USD 15.79 |
| Open | USD 15.91 |
| Day Range | USD 15.91 – 15.92 |
| 52-Week Range | USD 10.05 – 17.35 |
| Volume | 800 shares |
| Market Cap | $28.53B |
| Exchange | PNK |
Technical Analysis (ALPMY)
Nexqual's technical model rates ALPMY "BUY" based on 5 bullish and 3 bearish signals across 128 daily candles, as of October 23, 2026 at 16:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 73.75 (overbought) |
| vs SMA50 | Above (USD 14.85) |
| MACD | 0.25 (positive) |
Analyst Ratings (ALPMY)
Wall Street analysts rate ALPMY "Buy" based on 1 analysts, with a mean price target of USD 17.4 (range USD 17.4–17.4), per Nexqual as of October 23, 2026 at 16:39 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 17.4 |
| High Target | USD 17.4 |
| Low Target | USD 17.4 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ALPMY)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $594.09B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financials & Fundamentals (ALPMY)
| Total Revenue | $2.27T |
|---|---|
| Revenue Growth (latest quarter, YoY) | +26.70% |
| Gross Margin | +80.82% |
| Operating Margin | +28.92% |
| Profit Margin | +16.05% |
| ROE | +21.30% |
| Debt / Equity | 0.3 |
| Current Ratio | 1.2 |
| Total Cash | $244.70B |
| Total Debt | $589.87B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financial Health Score (ALPMY)
Nexqual rates Astellas Pharma Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 16:39 UTC.
| Growth | Strong — Revenue +171% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 81%, operating 29% (last 12 months) |
| Balance Sheet | Solid — JPY 244.7B cash vs JPY 589.9B debt |
| Cash Flow | Solid — Operating cash flow JPY 591.8B (TTM) |
| Efficiency | Strong — ROE 21%, ROA 8.4% |
Ownership (ALPMY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.02% |
| Shares Outstanding | 1.79B |
| Float | 1.79B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Leadership (ALPMY)
Astellas Pharma Inc. is led by Naoki Okamura BSc, President, CEO & Representative Director, per Nexqual as of October 23, 2026 at 16:39 UTC.
| President, CEO & Representative Director | Naoki Okamura BSc |
|---|---|
| Executive VP, Chief People Officer & Representative Director | Katsuyoshi Sugita |
| Chief Financial Officer | Atsushi Kitamura |
| Chief Scientific Officer & Senior Managing Executive Officer | Yoshitsugu Shitaka |
| President of Japan Commercial & Senior Corporate Executive | Nobuaki Tanaka |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIIB | Biogen Inc. | USD 250.61 | ▼ 1.27% |
| SNY | Sanofi | USD 41.48 | ▼ 1.14% |
| GSK | GSK plc | USD 50.6 | ▼ 1.19% |
| BMY | Bristol-Myers Squibb Company | USD 61.76 | ▼ 1.97% |
| GRFS | Grifols, S.A. | USD 7.55 | ▲ 1.28% |
| PFE | Pfizer, Inc. | USD 30.08 | ▼ 1.13% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt